BlossomHill Therapeutics IPO: Cancer Drug Developer Goes Public
The company went public on NASDAQ and raised $150 million
The company listed on NASDAQ under the ticker symbol BLSM. Photo: BlossomHill
Pre-market trading in shares of BlossomHill Therapeutics, a developer of small-molecule drugs for the treatment of cancer and autoimmune diseases, has begun on the Freedom client trading platform. The company’s lead candidate is a treatment for non-small cell lung cancer that could potentially compete with AstraZeneca’s blockbuster Tagrisso, according to Fierce BioTech. Later on August 7, BlossomHill Therapeutics shares will list on NASDAQ under the ticker BLSM. To participate, click on the BLSM ticker.
Details
BlossomHill Therapeutics successfully raised $150 million through its IPO. The company sold 9.38 million shares at $16 per share, which is in the middle of the previously announced price range ($15–17). Based on the IPO results, the company’s total valuation can be estimated at $490 million, according to Bloomberg.
The listing was organized by J.P. Morgan, Leerink Partners, Guggenheim Securities, LifeSci Capital, and H.C. Wainwright.
What Makes the Company Notable
BlossomHill, a San Diego-based company, was founded in 2020. It develops treatments for various types of cancer and autoimmune diseases. The company is led by its founder, Dr. J. Jean Kui, who previously served as a senior research scientist at Pfizer, according to Seeking Alpha.
According to a filing submitted by the company to the U.S. Securities and Exchange Commission (SEC), BlossomHill plans to allocate a significant portion of the funds raised during its IPO to its flagship drug in development—a treatment for non-small cell lung cancer (NSCLC). NSCLC is the most common form of lung cancer, accounting for about 85% of all cases.
With the launch of its lung cancer drug, BlossomHill is taking on pharmaceutical giant AstraZeneca and its blockbuster Tagrisso, according to Fierce Biotech. Currently, Tagrisso is the leading “first-line” treatment for patients with non-small cell lung cancer (NSCLC), generating more than $7 billion in revenue for the company worldwide last year (it is the first-line treatment prescribed to patients). Another potential competitor for BH-30643 on the market is Johnson & Johnson’s Rybrevant. BlossomHill also notes that other companies are developing similar drugs. However, in developing its drug, BlossomHill plans to focus on patients who have developed resistance to Tagrisso and other similar drugs, Fierce Biotech reports. BlossomHill’s BH-30643 is currently in the early stages of clinical trials.
The company’s portfolio also includes another anticancer drug—BH-30236. It is being developed for patients with relapsed or refractory (aggressive, unresponsive to standard chemotherapy) acute myeloid leukemia (AML). In the current Phase 1 study, the drug is being evaluated both as a monotherapy and in combination with venetoclax—the standard of care for many patients with AML. Updated safety and efficacy data for BH-30236 are expected in the first half of 2027.
As of March 31, 2026, BlossomHill had cash and cash equivalents of $116 million, while its total liabilities amounted to $38.7 million. For the three months ended March 31, the company reported a net loss of $21 million, compared with a loss of $10.5 million a year earlier.
Overall, since its founding, according to a filing submitted by BlossomHill to the U.S. Securities and Exchange Commission, the company has raised $257 million in funding from investors such as Cormorant, OrbiMed, Vivo Innovation, and Janus Henderson Biotech.
What People Are Saying in the Market
BlossomHill has joined the ranks of biotech companies that have been actively pursuing IPOs in recent weeks to take advantage of improved financing conditions in the sector following a prolonged downturn, Bloomberg notes.
Lung cancer is the leading cause of cancer-related deaths worldwide, so the potential market for the company’s drugs is enormous, says IPO Edge analyst Donovan Jones in a comment on Seeking Alpha. And it will only continue to grow, as people continue to smoke and the global population ages, he adds. According to a report by the research firm Grand View Research, the total global market for non-small cell lung cancer treatments was estimated at $21.5 billion in 2024 and is projected to reach $43.9 billion by 2030, Jones notes. Given this, BlossomHill’s drug may even be able to secure accelerated approval from the U.S. regulator, the expert says. The price at which Jones recommends buying BlossomHill shares—$16 per share—matches the IPO price.
Freedom Finance analyst Alem Bektemirov, for his part, says that at the current offering price, the company’s stock has 20.6% upside potential. His price target for the biotech stock is $19.30 per share. He identifies the main risks for BlossomHill as the possibility that the drug will not be approved by regulators, weak clinical trial results—which could significantly impact the stock price—and increased competition in the market.
___________________
Freedom clients will be able to access BlossomHill shares before the main trading session opens. Trading will begin in the early pre-market session 2–3 hours before the U.S. markets open (from 3:30 p.m. to 4:30 p.m. Astana time). To participate, click on the BLSM ticker.
This article was AI-translated and verified by a human editor
